← All themes
Theme

Biotech

Every analyzed stock in Biotech — 657 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Biotech risk
Near-term vs. long-term risk for this theme
⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months
44 /100 Elevated ▲ +2 slight
Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history
61 /100 High ◆ flat
▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.
Inside the "right now" score — a 45 / 30 / 25 blend · 118 stocks valued
Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.
50 Elevated
Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 118 stocks.
39 Moderate
Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.
45 Elevated
Smart money — the three inputs
Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.
49.0%
Elevated
Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.
55%
Elevated
Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.
30%
Moderate
Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 550 stocks (full universe); short-selling is market-wide.
Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.
Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
This week in Biotech
Biotech — Sep 7 – Sep 11, 2026 (Wk 37): Biotech Risk Score Rises; Novartis Faces Setback, Encoded Therapeutics Sees Investment →
The biotech sector's risk score increased this week, indicating a potentially more volatile environment. Novartis experienced a clinical trial failure, while RTW Biotech Opportunities made an additional investment in Encoded Therapeutics, highlighting continued activity in specific…
SCLXW
Scilex Holding Co
Valuation N/A
Healthcare Risk 77 · High
Price$0.11
Model IV—
P/IV—
Market implies -50.0%/yr vs model +25.0% · below model
SCNI
Scinai Immunotherapeutics Ltd.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$2.44
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
SCNX
Scienture Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.35
Model IV—
P/IV—
Market implies +41.0%/yr vs model +2.0% · above model
SDEV
Stablecoin Development Corp
Valuation N/A
Healthcare Risk 39 · Moderate
Price$0.86
Model IV—
P/IV—
Market implies -2.9%/yr vs model +15.0% · below model
SDGR
Schrodinger, Inc.
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$19.02
Model IV$4.40
P/IV3.46
Premium +332% Return to IV: -76.9%
Market implies +21.7%/yr vs model +16.7% · above model
SEED
Origin Agritech LTD
Valuation N/A
Basic Materials Risk 29 · Moderate
Price$1.05
Model IV—
P/IV—
Market implies +29.1%/yr vs model +8.0% · above model
SEER
Seer, Inc.
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$1.91
Model IV$0.88
P/IV2.12
Premium +116% Return to IV: -53.7%
Market implies +4.5%/yr vs model +25.8% · below model
SEPN
Septerna, Inc.
Undervalued
Healthcare Risk 36 · Moderate
Price$38.51
Model IV$41.19
P/IV0.73
Discount 7% Return to IV: +7.0%
Market implies +6.1%/yr vs model +10.0% · below model
SER
Serina Therapeutics, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.22
Model IV—
P/IV—
Market implies +85.0%/yr vs model +2.0% · above model
SGMT
Sagimet Biosciences Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$10.88
Model IV—
P/IV—
Market implies +81.2%/yr vs model +15.0% · above model
SILO
Silo Pharma, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$2.10
Model IV—
P/IV—
Market implies +83.2%/yr vs model +15.0% · above model
SION
Sionna Therapeutics, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$7.85
Model IV—
P/IV—
Limited data — see page
SLDB
Solid Biosciences Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$8.70
Model IV—
P/IV—
Market implies +70.7%/yr vs model +15.0% · above model
SLN
Silence Therapeutics plc
Valuation N/A
Healthcare Risk 31 · Moderate
Price$13.02
Model IV—
P/IV—
Market implies +129.4%/yr vs model +2.0% · above model
SLP
Simulations Plus, Inc.
Deeply overvalued
Technology Risk 59 · Elevated
Price$18.42
Model IV$10.79
P/IV1.59
Premium +71% Return to IV: -41.4%
Market implies +17.2%/yr vs model +13.6% · above model
SLS
SELLAS Life Sciences Group, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$11.55
Model IV—
P/IV—
Market implies +114.4%/yr vs model +15.0% · above model
SLXN
Silexion Therapeutics Corp
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.39
Model IV—
P/IV—
Limited data — see page
SLXNW
Silexion Therapeutics Corp
Valuation N/A
Healthcare Risk 44 · Elevated
Price$0.01
Model IV—
P/IV—
Limited data — see page
SMMT
Summit Therapeutics Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$17.55
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
SNDX
Syndax Pharmaceuticals Inc
Valuation N/A
Healthcare Risk 67 · High
Price$18.35
Model IV—
P/IV—
Market implies +18.0%/yr vs model +5.4% · above model
SNGX
SOLIGENIX, INC.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$0.36
Model IV—
P/IV—
Market implies +38.9%/yr vs model +15.0% · above model
SNTI
Senti Biosciences Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.31
Model IV—
P/IV—
Market implies +96.6%/yr vs model +2.0% · above model
SOPH
SOPHiA GENETICS SA
Valuation N/A
Technology Risk 32 · Moderate
Price$7.87
Model IV—
P/IV—
Limited data — see page
SPRB
SPRUCE BIOSCIENCES, INC.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$53.70
Model IV—
P/IV—
Market implies +33.9%/yr vs model +15.0% · above model
SPRO
Spero Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.13
Model IV—
P/IV—
Market implies -2.7%/yr vs model +42.3% · below model
SPTX
Seaport Therapeutics, Inc.
Valuation N/A
Healthcare Risk 51 · Elevated
Price$23.34
Model IV—
P/IV—
Limited data — see page
SRPT
Sarepta Therapeutics, Inc.
Undervalued
Healthcare Risk 50 · Elevated
Price$20.45
Model IV$22.12
P/IV0.81
Discount 8% Return to IV: +8.2%
Market implies +3.4%/yr vs model +32.1% · below model
SRRK
Scholar Rock Holding Corp
Valuation N/A
Healthcare Risk 50 · Elevated
Price$55.41
Model IV—
P/IV—
Market implies +71.2%/yr vs model +15.0% · above model
SRZN
Surrozen, Inc./DE
Valuation N/A
Healthcare Risk 42 · Elevated
Price$19.00
Model IV—
P/IV—
Limited data — see page
STOK
Stoke Therapeutics, Inc.
Deeply overvalued
Healthcare Risk 60 · High
Price$29.03
Model IV$9.85
P/IV3.14
Premium +195% Return to IV: -66.1%
Market implies +9.4%/yr vs model +15.0% · below model
STRO
SUTRO BIOPHARMA, INC.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$16.86
Model IV—
P/IV—
Market implies -4.2%/yr vs model +13.4% · below model
STTK
Shattuck Labs, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.20
Model IV—
P/IV—
Market implies +108.7%/yr vs model +2.0% · above model
STVN
Stevanato Group S.p.A.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$20.90
Model IV—
P/IV—
Limited data — see page
SVA
SINOVAC BIOTECH LTD
Fairly valued
Healthcare Risk 38 · Moderate
Price$6.47
Model IV$7.57
P/IV0.85
Discount 15% Return to IV: +17.0%
Market implies -9.9%/yr vs model +2.0% · below model
SVRA
Savara Inc
Valuation N/A
Healthcare Risk 42 · Elevated
Price$5.30
Model IV—
P/IV—
Limited data — see page
SWKHL
SWK Holdings Corp
Fairly valued
Financial Services Risk 49 · Elevated
Price$25.59
Model IV$23.58
P/IV1.08
Premium +9% Return to IV: -7.8%
Market implies -4.0%/yr vs model -1.4% · in line
SYRE
Spyre Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$90.95
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
TAK
TAKEDA PHARMACEUTICAL CO LTD
Valuation N/A
Healthcare Risk 37 · Moderate
Price$18.26
Model IV—
P/IV—
Limited data — see page
TARA
Protara Therapeutics, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$3.82
Model IV—
P/IV—
Limited data — see page
TARS
Tarsus Pharmaceuticals, Inc.
Deeply undervalued
Healthcare Risk 36 · Moderate
Price$79.31
Model IV$116.64
P/IV0.51
Discount 32% Return to IV: +47.1%
Market implies -8.8%/yr vs model +50.0% · below model
TCRT
Alaunos Therapeutics, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$1.51
Model IV—
P/IV—
Market implies +92.7%/yr vs model +2.0% · above model
TCRX
TScan Therapeutics, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$0.32
Model IV—
P/IV—
Market implies +60.9%/yr vs model +2.0% · above model
TECH
BIO-TECHNE Corp
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$72.34
Model IV$20.97
P/IV2.46
Premium +245% Return to IV: -71.0%
Market implies +23.8%/yr vs model +7.9% · above model
TECX
Tectonic Therapeutic, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$29.05
Model IV—
P/IV—
Limited data — see page
TELO
Telomir Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.17
Model IV—
P/IV—
Limited data — see page
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$37.09
Model IV$14.05
P/IV2.51
Premium +164% Return to IV: -62.1%
Market implies +16.9%/yr vs model +4.5% · above model
TGTX
TG THERAPEUTICS, INC.
Fairly valued
Healthcare Risk 47 · Elevated
Price$53.89
Model IV$42.77
P/IV0.89
Premium +26% Return to IV: -20.6%
Market implies -0.8%/yr vs model +50.0% · below model
THQ
abrdn Healthcare Opportunities Fund
Valuation N/A
Unknown
Price$18.92
Model IV—
P/IV—
Limited data — see page
THW
abrdn World Healthcare Fund
Valuation N/A
Unknown
Price$13.39
Model IV—
P/IV—
Limited data — see page
TIL
Instil Bio, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$7.38
Model IV—
P/IV—
Limited data — see page
TKNO
Alpha Teknova, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.71
Model IV—
P/IV—
Market implies +47.0%/yr vs model +2.4% · above model
TLSA
Tiziana Life Sciences Ltd
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.96
Model IV—
P/IV—
Limited data — see page
TLSI
TriSalus Life Sciences, Inc.
Deeply overvalued
Healthcare Risk 74 · High
Price$4.78
Model IV$1.56
P/IV2.19
Premium +207% Return to IV: -67.5%
Market implies +11.4%/yr vs model +15.0% · below model
TMO
THERMO FISHER SCIENTIFIC INC.
Deeply overvalued
Healthcare Risk 57 · Elevated
Price$613.62
Model IV$308.01
P/IV1.60
Premium +99% Return to IV: -49.8%
Market implies +14.5%/yr vs model +6.5% · above model
TNGX
Tango Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$23.89
Model IV—
P/IV—
Market implies +46.9%/yr vs model +13.9% · above model
TNYA
Tenaya Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$0.64
Model IV—
P/IV—
Limited data — see page
TOMZ
TOMI Environmental Solutions, Inc.
Valuation N/A
Basic Materials Risk 49 · Elevated
Price$1.62
Model IV—
P/IV—
Market implies +29.7%/yr vs model +0.0% · above model
TOVX
Theriva Biologics, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.25
Model IV—
P/IV—
Limited data — see page
TRAW
Traws Pharma, Inc.
Deeply undervalued
Healthcare Risk 47 · Elevated
Price$0.56
Model IV$1.16
P/IV1.26
Discount 51% Return to IV: +104.7%
Market implies -13.3%/yr vs model +50.0% · below model
TRAX
First Tracks Biotherapeutics, Inc.
Valuation N/A
Healthcare Risk 58 · Elevated
Price$36.44
Model IV—
P/IV—
Limited data — see page